Scoop: Novartis’ retreat on CAR-T includes axing most of its senior execs on the team
Novartis’ plan to pull back on CAR-T includes purging most of the senior execs involved in the project, signaling the pharma giant’s R&D retreat is more extensive than the company has wanted to admit so far.
Endpoints News, which broke the story on Novartis’ surprising R&D move, initially obtained the top fragment of an internal corporate memo authored by Usman “Oz” Azam at Novartis spelling out that the company is dissolving its cell and gene therapy unit responsible for its pioneering work on CAR-T. Now we have the rest of it, and it includes this on the team execs:
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters